ICD-10 M05.A is officially defined as "Abnormal rheumatoid factor and anti-citrullinated protein antibody with rheumatoid arthritis." code M05.A is referenced in 15 tracked payer policy changes from Blue Cross Blue Shield of North Dakota, Aetna, and 1 other payer. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code M05.A is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Blue Cross Blue Shield of North Dakota's August 2026 pharmacy update covers Medicaid Expansion medical drug prior authorization policies, with new policies and coding changes effective October 1, 2026. The most important billing change is the new HCPCS codes that replace older codes, such as Q5172 for Filkri and J9362 for Yondelis, plus added diagnosis codes for several drugs; the commercial pharmacy policies were reviewed with no changes listed.
Blue Cross Blue Shield of North Dakota updated its commercial pharmacy policies, and the revisions to the commercial prior authorization medical drug policies are effective September 9, 2026. Revisions to the commercial post service claim edit medical drug policies are effective August 1, 2026. Many of the prior authorization policies now state the number of days allowed for initial and renewal authorization durations, replace specific contraindications in the Universal Criteria with general language that the member does not have any FDA contraindications, and add covered ICD-10 diagnosis codes in Appendix 1.
Aetna considers measurement of antidrug antibodies and or serum drug levels for adalimumab, certolizumab, golimumab, or infliximab medically necessary for members with Crohn's disease or ulcerative colitis when there is documentation of a loss of response to one of these medications, or for proactive monitoring in members 21 years of age or younger with a confirmed diagnosis of IBD. Aetna considers serum antibody measurements for anti-TNF therapies experimental, investigational, or unproven for all other indications, such as psoriasis, psoriatic arthritis, rheumatoid arthritis, spondyloarthritis, and uveitis. Anti-histone antibody measurement for monitoring infliximab and DNA or mRNA biomarker measurement for predicting therapeutic response in IBD are also considered experimental, investigational, or unproven.
Independence Blue Cross updated policy 08.00.50ae to version 08.00.50af, effective 10/29/2025. Key changes include removal of generic ICD-10 code G35 (Multiple sclerosis) and addition of two new codes: G35.A (Relapsing-remitting multiple sclerosis) and M05.A (Abnormal rheumatoid factor and anti-citrullinated protein antibody with rheumatoid arthritis). These diagnosis code changes affect coverage determination for rituximab and related biosimilars.
Independence Blue Cross updated Medicare Advantage policy MA08.070f to MA08.070g, adding ICD-10 code M05.A (Abnormal rheumatoid factor and anti-citrullinated protein antibody with rheumatoid arthritis) to the covered diagnosis codes for Golimumab (Simponi Aria) IV injection. This expands coverage criteria for rheumatoid arthritis patients. The policy becomes effective October 1, 2025.
Independence Blue Cross Medicare Advantage policy MA08.070g for Golimumab (Simponi Aria IV) has been updated with a new ICD-10 diagnosis code M05.A (Abnormal rheumatoid factor and anti-citrullinated protein antibody with rheumatoid arthritis) effective 10/01/2025. Billing teams must ensure claims for golimumab IV injection include this newly added diagnosis code to support medical necessity for rheumatoid arthritis cases.
Independence Blue Cross updated MA08.022s to MA08.022t, effective 10/01/2025 and 10/29/2025, with ICD-10 diagnosis code changes for rituximab coverage. The broad diagnosis code G35 (Multiple sclerosis) was removed and replaced with the more specific G35.A (Relapsing-remitting multiple sclerosis), and a new rheumatoid arthritis code M05.A was added. Billing teams must update systems to reflect these revised diagnosis codes for rituximab authorization and claims processing.
Independence Blue Cross Medicare Advantage policy MA08.019q (effective 10/01/2025) supersedes MA08.019p and adds ICD-10 diagnosis code M05.A (Abnormal rheumatoid factor and anti-citrullinated protein antibody with rheumatoid arthritis) to the covered indications for intravenous infliximab and related biosimilars. Billing teams must update diagnosis code mappings and claim validation logic to recognize this new code as a medically necessary indication for infliximab coverage.
Independence Blue Cross added ICD-10 diagnosis code M05.A (Abnormal rheumatoid factor and anti-citrullinated protein antibody with rheumatoid arthritis) to policy 08.01.15h for Golimumab (Simponi Aria) IV injection coverage. This expands the diagnostic criteria for coverage eligibility under the existing medical necessity framework, effective October 1, 2025.
Independence Blue Cross updated policy 08.01.15h for Golimumab (Simponi Aria IV) effective 10/01/2025, adding new ICD-10 code M05.A for abnormal rheumatoid factor/anti-citrullinated protein antibody with rheumatoid arthritis, and removing numerous M05 and M06 codes (except M06.4) due to unspecified laterality. Billing teams must update diagnosis code validation rules to reflect these changes and ensure prior authorization aligns with the updated covered indications.
In inflammatory bowel disease (IBD) and rheumatoid arthritis, TPMT gene or phenotypic testing is medically necessary before starting 6-mercaptopurine or azathioprine, with only one TPMT assay per member per lifetime, and NUDT15 gene analysis is medically necessary before starting any thiopurine (azathioprine, mercaptopurine or thioguanine). For IBD, fecal calprotectin is medically necessary for managing Crohn's disease and ulcerative colitis and for distinguishing IBD from irritable bowel syndrome, fecal lactoferrin is medically necessary for distinguishing IBD from irritable bowel syndrome, and 6-thioguanine nucleotide and 6-methylmercaptopurine nucleotide measurements are medically necessary to monitor compliance in patients not responding to 6-mercaptopurine and azathioprine therapy and to assess suspected toxicity. Many other biomarkers, antibody panels and genetic tests, including NOD2/CARD15 genotyping, PredictSURE IBD, Monitr Crohn's Disease Test and procalcitonin measurement, are considered experimental, investigational or unproven.
Aetna considers HLA-B27 testing medically necessary for diagnosing ankylosing spondylitis and Reiter's syndrome (reactive arthritis), anti-CCP antibodies medically necessary for diagnosing rheumatoid arthritis, a myositis antibody panel medically necessary for diagnosing inflammatory myopathy, and anti-dsDNA antibodies medically necessary for evaluating and managing systemic lupus erythematosus. The UBA1 mutation test (QClamp Plex VEXAS) is medically necessary for detecting VEXAS syndrome in individuals aged 18 years or older who present with clinical features of the syndrome. Aetna considers the listed biomarker tests experimental, investigational or unproven because their effectiveness has not been established, including the aiSLE DX indices, PrismRA, Vectra DA, the Avise tests, anti-MCV antibodies, the Early Sjogren's Syndrome Profile, and anti-CCP antibodies for indications other than rheumatoid arthritis.
Aetna considers near-infrared vascular imaging and near-infrared fluorescence imaging experimental, investigational, or unproven for the indications listed in the policy. These include intra-operative fluorescence imaging of extra-hepatic bile ducts with indocyanine green for assessment of liver function, intra-parenchymal near-infrared spectroscopy for detection of delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage, sentinel lymph node detection with indocyanine green in cutaneous melanoma and oral squamous cell carcinoma, and Cision InVision short-wave infrared imaging for pathological imaging. Other listed indications include diagnosis of peripheral artery disease, diagnosis of rheumatoid arthritis, sentinel lymph node mapping in endometrial cancer, transcutaneous NIR spectroscopy for monitoring kidney and liver allograft perfusion, and near-infrared vascular imaging systems for assessment of cutaneous wound and guiding vascular access.
Independence Blue Cross updated Medicare Advantage policy MA08.028k effective 10/01/2025 to add ICD-10 diagnosis code M05.A (Abnormal rheumatoid factor and anti-citrullinated protein antibody with rheumatoid arthritis) to the covered diagnoses for Abatacept (Orencia) intravenous injection. This expands the conditions under which the drug may be considered medically necessary and covered for Medicare Advantage members.
Independence Blue Cross added ICD-10 diagnosis code M05.A (Abnormal rheumatoid factor and anti-citrullinated protein antibody with rheumatoid arthritis) to policy 08.00.62r for abatacept (Orencia) IV. This is a coding update that expands eligible diagnoses for coverage under existing medical necessity criteria. No changes to coverage criteria, billing codes, or prior authorization requirements.
Watch M05.A
Get one email when a payer policy names M05.A, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.